Praluent

Praluent

alirocumab

Manufacturer:

Sanofi

Distributor:

DCH Auriga - Healthcare
/
Four Star
Concise Prescribing Info
Contents
Alirocumab
Indications/Uses
Reduces risk of MI, stroke, & unstable angina requiring hospitalization in adults w/ established CV disease. As an adjunct to diet, alone or in combination w/ other lipid-lowering therapies (eg, statins, ezetimibe), for the treatment of adults w/ primary hyperlipidemia to reduce LDL-C.
Dosage/Direction for Use
SC Starting dose: 75 mg once every 2 wk. Alternative starting dose for patients who prefer less frequent dosing is 300 mg once every 4 wk (mthly). Max: 150 mg every 2 wk.
Contraindications
Special Precautions
Discontinue if signs or symptoms of serious allergic reactions occur. Patients w/ severe renal & hepatic impairment. Pregnancy & lactation. Childn.
Adverse Reactions
Nasopharyngitis, inj site reactions, flu, UTI, diarrhea, bronchitis, myalgia, muscle spasms, sinusitis, cough, contusion, musculoskeletal pain.
ATC Classification
C10AX14 - alirocumab ; Belongs to the class of other lipid modifying agents.
Presentation/Packing
Form
Praluent soln for inj 150 mg/mL
Packing/Price
1's
Form
Praluent soln for inj 75 mg/mL
Packing/Price
1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in